When using a CLDN18 positivity definition of moderate-to-strong membranous staining in ≥75% of tumor cells, as used in the SPOTLIGHT and GLOW trials, it was observed in 5.5% (13/237) of BTCs [36]. This evidence concerns the gene CLDN18 and neoplasm.